Pediatric Psoriasis Market Size, Share & Trends Analysis Report By Product (Systems, Accessories), By Patient Type (Adult, Pediatric), By End-Use, By Region, And By Segment Forecasts, 2025-2034
Global Pediatric Psoriasis Market Size is valued at USD 14.7 Bn in 2024 and is predicted to reach USD 47.7 Bn by the year 2034 at a 12.6% CAGR during the forecast period for 2025-2034.
Key Industry Insights & Findings from the Report:
- The expanding field of pediatric dermatology and the recognition of the unique challenges in treating skin conditions in children contribute to the development of specialized treatments, driving market growth.
- The challenge lies in developing effective and safe treatments suitable for the pediatric population.
- The pediatric segment is expected to account for the largest share of the global pediatric psoriasis market.
- North America dominated the largest market share in 2024.
Pediatric psoriasis, also known as childhood psoriasis, typically manifests as minor to moderate manifestations and is treatable with treatment. Pediatric psoriasis typically manifests as red, dry, and itchy skin patches, frequent pain, bleeding, and a variety of nail alterations, such as thick, pitted fingernails and nail yellowing. The global pediatric psoriasis market is anticipated to continue growing in revenue due to an increase in regulatory approvals for new and more potent psoriasis medications and treatments. The market has tremendous growth potential that investigators in developing nations have identified. Infantile psoriasis has a relatively limited number of approved therapeutic choices for the pediatric population.
Furthermore, major market competitors are making crucial efforts to diversify their product offerings to increase treatment options. Expanding government endeavors in pediatric psoriasis, rising R&D leading to the release of new medications, improved experience of rare diseases, and cost-effective therapy approaches are the factors driving the market during the projection period. Insufficient data in developing countries and limited funding for research may hinder the market. The market's overall growth is likely constrained by factors including the high cost of pediatric pediatric psoriasis therapies and the availability of resources. Additionally, major market competitors are making crucial efforts to diversify their product offerings to increase treatment options.
Competitive Landscape
Some Major Key Players In The Pediatric Psoriasis Market:
- AbbVie Inc.
- Amgen Inc
- Johnson & Johnson
- Novartis AG
- Eli Lilly & Company
- AstraZeneca
- Celgene Corporation
- UCB
- Merck
- Boehringer Ingelheim
- LEO Pharma
- Other Prominent Players
Market Segmentation:
The pediatric psoriasis market is segmented based on type, treatment, and end users. Based on type, the market is segmented as plaque psoriasis, guttate psoriasis, pustular psoriasis, inverse psoriasis, erythrodermic psoriasis, mucosal/oral psoriasis, nail psoriasis, napkin or diaper psoriasis, photosensitive psoriasis, flexural psoriasis. By application, the market is segmented into topical therapy, oral injections, biologics, natural supplements, and phototherapy. By end users, the market is segmented as hospitals, specialty clinics, ambulatory care centers, and research organizations.
Based On Type, The Plaque Psoriasis Segment Is Accounted As A Major Contributor To The Pediatric Psoriasis Treatment Market.
The plaque psoriasis sector is anticipated to have the biggest market share over the projection period. This is explained by the fact that children have the highest disease incidence. It is also the most prevalent type of psoriasis. These plaques appear most frequently on the knees, scalp, and elbows. These, though, can also be found in other bodily areas. These can hemorrhage and are unpleasant, irritating, and uncomfortable. It is unclear what specifically causes plaque psoriasis.
The Hospital's Segment Witnessed Growth At A Rapid Rate.
The hospital segment is projected to grow at a rapid rate in the global pediatric psoriasis market. The increased adoption of therapies and widespread hospital use contribute to the growth. Therefore, researchers would have a favorable market impact by developing potent, secure drugs and dosages. One of the main drivers of this segment's revenue growth is the rise in pediatric psoriasis instances that are severe, the rate of hospital admissions, and the quick acceptance of safer and more effective medications and therapies., especially in countries such as the US, Germany, UK, China, and India.
The North American Pediatric Psoriasis Market Holds A Significant Regional Revenue Share.
The North American pediatric psoriasis market is expected to register the highest market share in revenue soon. Due to the rising prevalence of the condition, North America now controls the plaque psoriasis market. Additionally, a potent drug pipeline in the region would help the pediatric psoriasis market throughout the projection period.
Asia Pacific region is estimated to hold a significant share of the market. The pediatric psoriasis market is anticipated to experience considerable expansion in Asia-Pacific because of the rise in research investment. Moreover, the region's plaque psoriasis market is anticipated to rise over the next several years because of growing public awareness of the condition.
Recent Developments:
- In March 2024, Amgen has recently disclosed the 52-week results of the Phase 3 SPROUT study, which investigated the efficacy of Apremilast (Otezla®) in children and adolescents with moderate to serious plaque psoriasis aged 6 to 17 years. These results, in addition to those from a Phase 3 late-breaking study on Otezla for palmoplantar pustulosis, will be presented at the 2024 Annual Meeting of the AAD i.e. American Academy of Dermatology, which will be held in San Diego from March 8-12.
- In June 2021, The FDA approved Novartis Cosentyx for the management of mild to serious plaque psoriasis in children and adolescents. Plaque psoriasis, an inflammatory chronic disease, had the potential to affect approximately 350,000 children globally, with adolescence being the most prevalent age of onset.
Pediatric Psoriasis Market Report Scope
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 14.7 Billion |
| Revenue Forecast In 2034 | USD 47.7 Billion |
| Growth Rate CAGR | CAGR of 12.6% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Bn,and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Type, Treatment, End-Use |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
| Competitive Landscape | AbbVie Inc., Amgen Inc, Johnson & Johnson, Novartis AG, Eli Lilly & Company, AstraZeneca, Celgene Corporation, UCB, Merck, Boehringer Ingelheim, LEO Pharma, Other Prominent Players. |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Segmentation Of Pediatric Psoriasis Market
By Type
- Plaque psoriasis
- Guttate psoriasis
- Pustular psoriasis
- Inverse psoriasis
- Erythrodermic psoriasis
- Mucosal/oral psoriasis
- Nail psoriasis
- Napkin or diaper psoriasis
- Photosensitive psoriasis
- Flexural psoriasis
By Treatment
- Topical therapy
- Oral
- Injections
- Biologics
- Natural supplements
- Phototherapy
Bend Use
- Hospitals
- Specialty Clinics
- Ambulatory Care Centers
- Research Organizations"
By Region-
North America-
- The US
- Canada
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Pediatric Psoriasis Market Size is valued at USD 14.7 Bn in 2024 and is predicted to reach USD 47.7 Bn by the year 2034
Pediatric Psoriasis Market is expected to grow at a 12.6% CAGR during the forecast period for 2025-2034
AbbVie Inc., Amgen Inc, Johnson & Johnson, Novartis AG, Eli Lilly & Company, AstraZeneca, Celgene Corporation, UCB, Merck, Boehringer Ingelheim, LEO P
Type, Treatment and End-Use are the key segments of the Pediatric Psoriasis Market.
North America region is leading the Pediatric Psoriasis Market